(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 November 2014 (06.11.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/179448 A3

(51) International Patent Classification:
A61K 38/17 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2014/036140

(22) International Filing Date:
30 April 2014 (30.04.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/818,220 1 May 2013 (01.05.2013) US
61/831,029 4 June 2013 (04.06.2013) US

(71) Applicants: **FIVE PRIME THERAPEUTICS, INC.** [US/US]; Two Corporate Drive, South San Francisco, California 94080 (US). **GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED** [GB/GB]; 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(72) Inventors: **HAMBLETON, Julie**; Two Corporate Drive, South San Francisco, California 94080 (US). **BLEAM, Maureen R.**; 980 Great West Road, Brentford Middlesex TW8 9GS (GB). **DEYOUNG, Maurice P.**; 980 Great West Road, Brentford Middlesex TW8 9GS (GB). **FERRON-BRADY, Geraldine**; 980 Great West Road, Brentford Middlesex TW8 9GS (GB). **KUMAR, Rakesh**; 980 Great West Road, Brentford Middlesex TW8 9GS (GB). **OTTESEN, Lone**; 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(74) Agent: **SCARR, Rebecca B.**; 2275 Deming Way, Suite 310, Middleton, Wisconsin 53562 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
24 December 2014

WO 2014/179448 A3

(54) Title: METHODS OF TREATING CANCER

(57) Abstract: Methods of treating cancers comprising *FGFR1* gene amplification, FGFR1 overexpression, FGFR3 overexpression, *FGFR3* amplification, FGF2 overexpression, and/or *FGF2* gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. In some embodiments, methods of treating cancers comprising administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one chemotherapeutic agent are provided.